Statins: Could an old friend help the fight against COVID-19?
Entity
UAM. Departamento de MedicinaPublisher
WileyDate
2020-06-19Citation
10.1111/bph.15166
British Journal of Pharmacology 177.21 (2020): 4811-5001
ISSN
0007-1188 (print); 1476-5381 (online)DOI
10.1111/bph.15166Funded by
This work and data discussed here were supported by grants from the Instituto de Salud Carlos III (ISCIII) and Fondos FEDER European Union (PI17/00119 and Red de Investigación Renal (REDINREN): RD16/0009, to M.R-O, PI17/01495 to J.E, PI18/01133 to AMR, PI19/00815 to A.O); Comunidad de Madrid (“NOVELREN” B2017/BMD3751 to M.R-O, B2017/BMD-3686 CIFRA2-CM to A.O); Spanish Ministry of Economy and Competitiveness MINECO (DTS17/00203, DTS19/00093) to J,E; “Convocatoria Dinamización Europa Investigación 2019” MINECO (EIN2019-103294 to M.R-O and SR-M); ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071) and DTS18/00032 to A.O; The “Sara Borrell” postdoctoral training program of the ISCIII supported the salary of SR-M (CD19/00021), IMPROVE-PD project (“Identification and Management of Patients at Risk–Outcome and Vascular Events in Peritoneal Dialysis”) funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement No. 812699 to M.R.O.Project
info:eu-repo/grantAgreement/EC/H2020/812699/EU//IMPROVE-PD; Gobierno de España. PI17/00119; Gobierno de España. RD16/0009; Gobierno de España. PI17/01495; Gobierno de España. PI18/01133; Comunidad de Madrid. B2017/BMD3751/NOVELREN; Comunidad de Madrid. B2017/BMD-3686/CIFRA2-CM; Gobierno de España. DTS17/00203; Gobierno de España. DTS19/00093; Gobierno de España. EIN2019-103294; Gobierno de España. AC18/00064; Gobierno de España. AC18/00071; Gobierno de España. DTS18/00032Editor's Version
https://doi.org/ 10.1111/bph.15166Subjects
Statins; COVID-19; SARS-CoV-2 receptors; ACE2; CD147; autophagy; lipid rafts; inflammation; inflammasome; coagulation; MedicinaNote
This is the peer reviewed version of the following article: "Statins: Could an old friend help the fight against COVID-19?" . British Journal of Pharmacology (2020): 19 June, which has been published in final form at https://doi.org/10.1111/bph.15166. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived VersionsRights
© 2020 The British Pharmacological SocietyAbstract
he COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has overwhelmed healthcare systems requiring the rapid development of treatments, at least, to reduce COVID-19 severity. Drug repurposing offers a fast track. Here, we discuss the potential beneficial effects of statins in COVID-19 patients based on evidence that they may target virus receptors, replication, degradation, and downstream responses in infected cells, addressing both basic research and epidemiological information. Briefly, statins could modulate virus entry, acting on the SARS-CoV-2 receptors, ACE2 and CD147, and/or lipid rafts engagement. Statins, by inducing autophagy activation, could regulate virus replication or degradation, exerting protective effects. The well-known anti-inflammatory properties of statins, by blocking several molecular mechanisms, including NF-κB and NLRP3 inflammasomes, could limit the "cytokine storm" in severe COVID-19 patients which is linked to fatal outcome. Finally, statin moderation of coagulation response activation may also contribute to improving COVID-19 outcomes
Files in this item
Google Scholar:Rodrigues-Diez, Raul R.
-
Tejera-Muñoz, Antonio
-
Marquez-Exposito, Laura
-
Rayego-Mateos, Sandra
-
Santos Sanchez, Laura
-
Marchant, Vanessa
-
Tejedor Santamaria, Lucía
-
Ramos, Adrian M.
-
Ortiz Arduán, Alberto
-
Egido, Jesús
-
Ruiz Ortega, Marta
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.